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ABSTRACT
The specific silencing of the gene of interest is
the major objective of RNA interference technol-
ogy; therefore, unique sequences but not abun-
dant sequence repeats are targeted by silencing
reagents. Here, we describe the targeting of
expanded CAG repeats that occur in transcripts
derived from the mutant allele of the gene
implicated in Huntington’s disease (HD) in the
presence of the normal allele and other human
mRNAs containing CAG and CUG repeat tracts.
We show that a high degree of silencing selectivity
may be achieved between the repeated sequences.
We demonstrate preferential suppression of the
mutant huntingtin allele and concomitant activation
of the normal huntingtin allele in cell lines derived
from HD patients that were transfected with short
RNA duplexes composed of CAG and CUG re-
peats containing mutations at specific positions.
These effects may lead to promising therapeutic
modalities for HD, a condition for which no therapy
presently exists.
INTRODUCTION
Almost 20 human genetic diseases are caused by speciﬁc
trinucleotide repeat expansions in different single genes
(1). The best known of these diseases are fragile X
syndrome (FXS), myotonic dystrophy type 1 (DM1),
Huntington’s disease (HD) and a number of
spinocerebellar ataxias (SCA). The mechanisms of patho-
genesis differ between these diseases and include impaired
transcription (FXS), transcript toxicity (DM1) and
protein toxicity (HD and SCAs) (2,3). In several SCAs
and HD, the expanded CAG repeats present in the open
reading frame (ORFs) of the implicated genes (ATXN and
HTT, respectively) are translated into polyglutamine
tracts in the encoded, functionally unrelated proteins.
This subgroup is commonly referred as the polyglutamine
(polyQ) diseases. Pathogenesis in polyQ diseases is trig-
gered by a single mutant allele of the particular gene,
which acts in a dominant ‘gain-of-function’ fashion.
Therefore, the allele-speciﬁc inhibition of mutant gene ex-
pression is considered a promising strategy for establish-
ing causative therapies for these diseases. Mutant
transcript silencing by RNA interference (RNAi) has
been attempted in several studies. Single nucleotide poly-
morphisms (SNPs) linked to repeat expansions were
targeted (4–6). The efﬁciency of this approach has
increased with the advances in single nucleotide difference
discrimination by RNAi reagents (7–9). SNP targeting,
however, is limited by the low frequencies of suitable
SNPs in the human population, and prospective treat-
ments need to be tailored to individual patients. The
recent identiﬁcation of speciﬁc SNPs associated with
CAG repeat expansion in HTT may increase the potential
of this strategy (10). Non-allele-speciﬁc inhibition of HTT
gene expression by RNAi has also been shown to offer
some advantages (11–14).
The speciﬁc inhibition of mutant allele expression by
targeting expanded CAG repeats could be developed
into a more universal therapeutic approach that would
potentially be applicable to all polyQ diseases. But how
could it be possible to selectively silence a mutant allele
containing  40–100 CAG repeats and discriminate it
from both the normal allele and the numerous other
human transcripts typically containing <20 CAG
repeats? The RNAi approach was initially abandoned
after discouraging results were obtained using
repeat-targeting siRNAs. Both alleles of HTT and
ATXN3 genes were shown to be silenced in cell culture
in response to 21-nt siRNA duplexes composed of
CUG/CAG repeats (5,15). Recently, a high degree of se-
lectivity in mutant HTT allele inhibition has been achieved
using repeat-targeting PNA and LNA antisense reagents
(15). The allele-discriminating abilities of these reagents
were considerably stronger than those of repeat-targeting
siRNA.
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targeting RNA duplexes to discriminate between the
mutant and the normal HTT transcript to achieve the
desired allele selectivity. We also analyzed the gene select-
ivity of CAG/CUG duplexes, which is understood as dis-
crimination between HTT and other mRNAs containing
CAG and CUG repeat tracts. We observed some modest
discrimination between mutant and normal HTT alleles
by repeat-targeting siRNA. Then, we introduced muta-
tions at speciﬁc positions of the repeat-targeting duplex
what improved its gene and allele selectivity. Gene select-
ivity was further improved through CAG strand inactiva-
tion, which was achieved by reducing its length. We also
provide ﬁrst clues for the mechanism by which preferential
mutant huntingtin inhibition and concomitant normal
huntingtin activation may occur.
MATERIALS AND METHODS
Cell culture and transfection
Fibroblasts from HD patients (GM04281—17/68 CAG,
GM09197—21/151 CAG, GM04208—21/44 CAG,
GM01187—18/47 CAG) and SCA3 patients
(GM06153—18/69 CAG), obtained from the Coriell Cell
Repositories, were grown in minimal essential medium
(Lonza) supplemented with 8% fetal bovine serum
(Sigma), antibiotics (Sigma) and non-essential amino
acids (Sigma). Cell transfections were performed using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Transfection efﬁciency was moni-
tored using a BlockIT ﬂuorescent siRNA (Invitrogen).
All RNA oligonucleotides were synthesized by
Metabion. The sequences of the synthetic RNAs used in
this study are presented in Figures.
RNA isolation and RT–PCR
Total RNA was isolated from ﬁbroblast cells using TRI
Reagent (BioShop) according to the manufacturer’s in-
structions. The RNA concentration was measured using
a NanoDrop spectrophotometer. A total of 500ng RNA
was reverse transcribed using Superscript II (Invitrogen)
and random hexamer primers (Promega). The quality of
the reverse transcription (RT) reaction was assessed using
ampliﬁcation of the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) housekeeping gene. Primer se-
quences are listed in Supplementary Table S1. The
reaction products were separated on 1.5% agarose gels
in TBE buffer and stained with ethidium bromide.
Protein isolation and western blot
Fibroblast cells were lysed in buffer containing 60mM
Tris-base, 2% SDS, 10% sucrose and 2mM PMSF. The
protein concentration was estimated using a NanoDrop
spectrophotometer. A total of 20mg of protein was
diluted in sample buffer containing 2-mercaptoethanol
and boiled for 5min. For ataxin-3 ( 40kDa) and
huntingtin ( 350kDa) level analyses, different proteins
were selected as controls of total protein levels: GAPDH
( 35kDa) and plectin ( 500kDa), respectively. Plectin is
not a standard protein loading control, but in our experi-
ments, we demonstrated that the level of plectin remained
unchanged after cell transfection with RNAs. This was
done by comparing the GAPDH and plectin levels from
the same protein lysate. Therefore, this protein was used
as a reliable gel loading control for huntingtin detection.
For ataxin-3, RPL14, LRP8, EIF2AK3 and GAPDH de-
tection the proteins were separated using Tris–HCl SDS–
polyacrylamide gel electrophoresis (5% stacking/12%
resolving gel) in Laemmli buffer. For huntingtin and
plectin electrophoresis a Tris–acetate SDS–polyacryl-
amide gel was used (5% stacking/4% resolving gel) and
run in XT Tricine buffer (Bio-Rad) with cooling to 15 C.
After electrophoresis, the proteins were wet-transferred to
a nitrocellulose membrane. The membranes were cut ac-
cording to protein ladders for separate detection of re-
spective proteins. All steps of immunodetection were
performed on a SNAPid (Millipore) in buffer containing
0.25% non-fat milk in PBS/0.9% NaCl/0.1% Tween-20.
For ataxin-3/GAPDH or RPL14, LRP8, EIF2AK3/
GAPDH detection, the blots were probed with the
primary antibodies anti-ataxin-3 (1:1000), anti-RPL14
(1:500), anti-LRP8 (1:500), anti-EIF2AK3 (1:500) and
anti-GAPDH (1:5000) and then with a biotinylated
secondary antibody (1:500); they were then incubated
with a streptavidin–AP conjugate (1:2000, Millipore).
The immunoreaction was detected using the BCIP/NBT
substrate (Sigma). For huntingtin/plectin detection the
blots were probed with the primary antibodies:
anti-huntingtin (1:1000) and anti-plectin (1:1000) and
then with HRP-conjugated secondary antibodies (1:500).
The immunoreaction was detected using ECL Western
Blotting Substrate (ThermoScientiﬁc). Examples of
huntingtin alleles separation and examples of full blots
for ataxin-3 and huntingtin level analysis are shown in
Supplementary Figure S1. All antibodies are listed in
Supplementary Table S2.
Cell viability assay
The effect of RNA reagents on cell mortality was assessed
using the CellTiter-Glo Luminescent Cell Viability Assay
(Promega) based on quantitation of adenosine-50-
triphosphate (ATP).
50-RACE
Total RNA from transfected SCA3 or HD cells was
ligated with 45nt adaptor RNA using T4 RNA Ligase
(Ambion) and then reverse transcribed using random
hexamers (Promega) and SuperScript II (Invitrogen).
First step ampliﬁcations were performed with Ad_ex and
ATXN3_ex primer pair. Then, after 20  dilution of the
product, nested PCR was performed with Ad_int and
ATXN3_int primer pair. Primer sequences are listed in
Supplementary Table S1. Prior to nested PCR the
Ad_int primer was 50-end-labeled with [g-
32P]ATP using
T4 polinucleotide kinase (Epicentre). Final PCR products
were diluted 20  in formamide buffer with dyes and
analyzed on a 6 % polyacrylamide–7.5M urea gel. The
electrophoresis was run in a 1  TBE buffer. The products
Nucleic Acids Research, 2011,Vol.39, No. 13 5579were detected by autoradiography, eluted from a gel,
re-ampliﬁed and sequenced.
Statistical analysis
All experiments were repeated at least three times. The
statistical signiﬁcance of silencing or up-regulation was
assessed with a one-sample t-test with the hypothetical
value 1 assigned to untreated cells (0) or cells treated
with control siRNA (C). Selected data were compared
with each other with the use of an unpaired t-test.
P-values (two-tailed) that were<0.05 were considered
signiﬁcant.
RESULTS
Both strands of the d7-duplex silence transcripts having
complementary sequences
Duplex d7 is composed of a pure CUG and CAG repeat
sequences and its 21nt strands are predicted to form 1nt 30
overhangs (Figure 1A). When d7 is transfected into cells
either the CUG or the CAG strand may activate RISC to
become functional in RNAi. To demonstrate this, we
analyzed the silencing activities of the CUG and CAG
guide strands against selected transcripts containing at
least seven CAG (HTT, ATXN1 and ATXN3) or CUG
repeats (RPL14, LRP8 and EIF2AK3) in HD ﬁbroblast
cell line GM04281 (CAG 17/68 in HTT mRNA). Similar
results were obtained for the 21-nt (d7) and 27-nt (d9)
siRNAs: both strands of tested reagents were found to
be active in silencing transcripts, even at the lowest
siRNA concentrations used (Figure 1B and C). On the
other hand, the activity of the shorter duplex formed by
the 17-nt long CAG and CUG repeat strands was low
(data not shown). We also analyzed the efﬁciency of
HTT transcript silencing by d7 reagent in broader range
of concentration (Supplementary Figure S2). We observed
some preference for mutant transcript silencing at all con-
centrations tested, and the transcript level decreased con-
siderably at concentrations as low as 0.25nM.
Speciﬁc mutations in d7 increase its preference for mutant
HTT allele silencing
We attempted to increase both the gene selectivity and the
allele selectivity of repeat-targeting duplex by selecting the
mutations that decreased the strength of programmed
RISC interactions with respective targets. To achieve
this goal, we introduced either single or double C>U sub-
stitutions at positions 13 (W13), 16 (W16) and both 13 and
16 (W13/16) as well as at positions 1 and 19 (W1/19) of the
d7 CUG strand (Figure 2A). Both siRNA strands were
mutated to maintain their complementarities. This
required G>A substitutions at positions 2, 5, 8 and 20
in the CAG strand. The mutant duplexes were transfected
at 20nM to HD ﬁbroblasts (GM04281). We tested the
activities of the duplexes on both HTT allelic variants
and the same set of previously mentioned CAG repeat-
and CUG repeat-containing transcripts. All these
duplexes showed decreased activities as compared to d7,
and the strongest decreases were shown for W13 and W13/
16 by reverse transcriptase polymerase chain reaction
(RT–PCR) analysis (Figure 2B). Protein analysis showed
that W16 and W1/19 were similar to d7 with respect to
their silencing efﬁciencies and allele selectivities
(Figure 2C). In contrast, W13 and W13/16 showed
strong preferences for mutant huntingtin inhibition.
These reagents resulted in decreased mutant protein
levels to  25% of the untreated control level (Figure
2C). Similar results were obtained for the testing of the
set of duplexes in the other HD cell line GM09197
(CAG 21/151) (Supplementary Figure S3). Protein
Figure 1. CUG repeat and CAG repeat strands are active in transcript silencing. (A) Sequences of d7 and d9 duplexes (B) RT-PCR analysis of
cellular levels of CAG-containing (HTT, ATXN1 and ATXN3) and CUG-containing transcripts (RPL14, LRP8 and EIF2AK3) 24h after
transfection of HD ﬁbroblasts (GM04281) with d7 (CAG/CUG-21nt) or d9 (CAG/CUG-27nt) at 2, 10 and 50nM. (C) Bar graph shows cellular
levels of analyzed transcripts for the experiment described in (B). Reference bars indicate transcript expression levels in non-transfected cells (0), cells
treated with Lipofectamine 2000 only (L) and cells transfected with control siRNA (C). In all graphs, signal intensities were normalized to GAPDH
mRNA and compared using a one-sample t-test. Error bars represent standard deviations. The P-value is indicated by an asterisk (*P<0.001).
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with different concentrations of W13 and W13/16. For
both duplexes, 5nM effectively inhibited mutant protein
levels, and concentrations as high as 100nM did not
reduce normal protein levels (Figure 2D). Moreover, we
observed reproducible up-regulation of normal huntingtin
by W13 and W13/16 transfection (Figure 2C and D). A
similar trend of W13/16 activity was observed for other
tested HD cell lines, GM4208 (CAG 21/44) and GM01187
(CAG 18/47), representing the lengths of CAG repeat
tracts which are more typical for HD patients
(Supplementary Figure S4).
Elimination of CAG strand activity improves the gene
selectivity of mutant duplexes
The mutations present in W13 and W13/16 strongly
increased the allele selectivity and improved the gene se-
lectivity of HTT silencing, but they did not sufﬁciently
reduce the silencing of transcripts other than HTT. To
retain the advantageous features of W13 and W13/16
and further improve their gene selectivity, we inactivated
the CAG strand by shortening it to 17 or 16nt. We tested
the asymmetric siRNAs (Figure 3A) for their HTT protein
inhibitory activity, and for their ability to silence the CUG
repeat-containing transcripts. These duplexes inhibited the
HTT protein with allele selectivities similar to that of their
symmetric counterparts when used at 100nM (Figure 3B).
At 20nM, their activities were considerably lower than
those of the symmetric duplexes (data not shown). The
asymmetric duplexes were considerably less effective in
silencing the CUG repeat-containing transcripts, so an
improvement in their gene selectivity (reduction of their
off-target effect) was achieved (Figure 3C).
Different RNA duplexes silence the HTT gene through
different mechanisms
The preferential inhibition of mutant HTT protein synthe-
sis by W13/16, which was observed 72h post-transfection
(Figure 2), required conﬁrmation using a more detailed
analysis of the silencing process. The changes of both
HTT protein and transcript levels were analyzed for
6 days after W13/16 transfection in 24-h intervals
(Figure 4A) and compared to the effects brought about
by d7 (Figure 4B). The mutant protein was effectively
silenced starting from Day 2 after W13/16 transfection,
but cellular levels of the mutant transcript remained un-
changed (Figure 4A and Supplementary Figure S5A).
At the same time, an  2-fold increase in normal transcript
Figure 2. Silencing activity of mutated CAG/CUG duplexes. (A) Sequences of modiﬁed duplexes with mutated positions indicated. (B) Results from
the RT-PCR analysis of CAG-containing (HTT, ATXN1 and ATXN3) and CUG-containing transcript (RPL14, LRP8 and EIF2AK3) levels 24h
after transfection of HD ﬁbroblasts (GM04281, 17/68 CAG in HTT) with 20nM of modiﬁed duplexes or d7. (C) Western blot analysis of huntingtin
levels for the experiment described in (B) After 72h transfection. (D) Western blot analysis of huntingtin levels 72h after transfection of HD
ﬁbroblasts with 5, 20 and 100nM W13 or W13/16. Reference bar ‘C’ indicates HTT expression levels in cells transfected with control siRNA. In all
graphs, signal intensities were normalized to GAPDH mRNA or plectin protein levels and compared using a one-sample t-test. Error bars represent
standard deviations. The P-value is indicated by an asterisk (*P<0.001; **0.001<P<0.05). More examples of raw data are presented in
Supplementary Figure S10.
Nucleic Acids Research, 2011,Vol.39, No. 13 5581levels was observed, and resulted in smaller increase in
normal HTT protein levels. In contrast, both mutant
and normal transcript and protein levels decreased after
d7 treatment (Figure 4B and Supplementary Figure S5B),
conﬁrming our observations made at the selected single
time points. The same pair of reagents was then tested
for any preferential silencing of mutant or normal
ATXN3 transcripts or proteins in the cellular model of
SCA3. The d7 transfection displayed similar silencing
activities in SCA3 cells as compared to the HD cells
(Figure 4D and Supplementary Figure S5D), but no
allele discrimination comparable to that achieved in HD
cells was induced by W13/16 (Figure 4C and
Supplementary Figure S5C). Nevertheless, we
demonstrated up-regulation of normal HTT transcript
also in SCA3 cells (Supplementary Figure S6). W13/16
showed reduced silencing of proteins encoded by CUG
repeat-containing transcripts: RPL14, LRP8 and
EIF2AK3, as compared to d7 (Supplementary
Figure S7). We then performed 50-RACE analysis to
assess whether transcript cleavage occurred in d7 and
W13/16 treated cells due to RNAi mechanism. We used
three repeat-targeting duplexes d7, d7-2 and d7-3, each
having guide sequences that were shifted by 1nt.
Sequences of the corresponding 50-RACE products and
established cleavage sites showed that the
AGO2-mediated cleavage mechanism contributed to the
activity of all tested reagents (Supplementary Figure S8).
This contribution, however, is very likely to be substantial
in case of d7 activity and marginal in case of W13/16
activity. For W13/16-activity duplex structure was
required, as the transfection of HD ﬁbroblasts with
W13/16 antisense or sense strand alone, caused neither
downregulation nor up-regulation of mutant and normal
huntingtin (Supplementary Figure S9).
Duplexes with better gene selectivity are less toxic to cells
An important issue regarding the application of
repeat-targeting reagents is their potential toxicity to
cells, which may primarily be caused by their
compromised gene selectivity. We analyzed the toxicity
of the different types of reagents tested in this study,
Figure 3. Silencing activity of improved mutated CAG/CUG duplexes. (A) Sequences and preferential structures formed by d7-, W13- or W13/
16-based duplexes with a shortened CAG strand. Mutated positions are indicated. (B) Western blot analysis of huntingtin level 72h after transfection
of HD ﬁbroblasts (GM04281) with 100nM of the reagents listed in (A). (C) Results from the RT–PCR analysis of CAG-containing (HD, ATXN1
and ATXN3) and CUG-containing transcript (RPL14, LRP8 and EIF2AK3) for the experiment described in (B) 24h post-transfection. Reference
bar ‘C’ indicates HTT expression levels in cells transfected with control siRNA. In all graphs, signal intensities were normalized to GAPDH mRNA
or plectin protein levels and compared using a one-sample t-test. Error bars represent standard deviations. The P-value is indicated by an asterisk
(*P<0.001; **0.001<P<0.05). More examples of raw data are presented in Supplementary Figure S10.
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Figure 5, the greatest decrease in viable cells was
detected in response to d7. Transfection with this
reagent at 20nM resulted in  50% reduction in the cell
number. Cell viability was positively correlated with
increased gene selectivity of tested reagents, as W13/16
and its asymmetric version (W13/16-16/21-II) induced sig-
niﬁcantly lower mortality of cells.
DISCUSSION
CAG and CUG repeats are often polymorphic in length
and are among the most frequently occurring triplet
repeats in the human transcriptome (16). Nearly 200
mRNAs contain CAG repeat tracts, and >100 mRNAs
Figure 4. Time course analysis of d7 and W13/16 activity. RT–PCR and western blot analyses of HTT (A and B) and ATXN3 (C and D) transcript
and protein levels after transfection of HD (GM04281) or SCA3 ﬁbroblasts (GM06153) with 20nM W13/16 (A, C) or d7 (B and D) at indicated time
points. Reference point ‘C’ indicates HTT expression levels in cells transfected with control siRNA. In the graphs mean values from signal intensities
are presented, for statistical analysis see Supplementary Figure S5.
Figure 5. Toxicity of speciﬁc and repeat-targeting reagents. Results
from cell viability assay 72h after transfection of HD ﬁbroblasts
(GM04281) with control siRNA (C), speciﬁc siRNA (HD1) and
repeat-targeting duplexes at 5, 20 and 100nM. (0) reference bar,
non-transfected cells, (L) cells treated with Lipofectamine 2000 only.
Normalized signal intensities were compared using a one-sample t-test.
Error bars represent standard deviations. The P-value is indicated by
an asterisk (*P<0.001; **0.001<P<0.05).
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repeated units (17). This makes the repeat-targeting thera-
peutic strategy quite challenging. We showed that RISC,
programmed by either strand of the repeat-targeting
CAG/CUG siRNA (d7), was highly active in the silencing
of several normal transcripts containing complementary
sequences, what resulted in signiﬁcant loss of cell viability.
In recent years, several rules have been proposed for the
design of efﬁcient allele-speciﬁc siRNAs, targeting single
nucleotide polymorphism sites in RNAs. These rules
showing the importance of speciﬁc nucleotides and nu-
cleotide positions for allele discrimination (7,8) have
provided some clues on how to increase the selectivity of
the CAG repeat-targeting duplex. Our strategy was to
introduce speciﬁc mutations at selected d7 positions to
modulate RISC activity. The mutations at positions 13
and 16 of the antisense strand were selected as these pos-
itions were among the ones providing the strongest allele
discrimination (8,9). By applying this strategy in the
design of the W13 and W13/16 duplexes, we achieved
improved gene selectivity and allele selectivity of mutant
HTT allele silencing. The gene selectivity of the W13 and
W13/16 duplexes was further increased by taking advan-
tage of recent developments in asymmetric siRNA design
(18,19). However, to achieve efﬁcient silencing of mutant
huntingtin, the asymmetric duplexes had to be used at a
higher concentration than their symmetric counterparts.
Increased gene selectivity was positively correlated with
cell viability after transfection with reagents composed
of CAG/CUG repeats. It may be speculated that the
similar toxicity order of the reagents composed of
repeats will be observed in neurons which are predomin-
ant sites of HD pathology.
Notably, d7, which possessed full complementarity to
its HTT target, and the W13 and W13/16 duplexes, having
either one or two G:U mismatches, silenced the expression
of the mutant HTT allele very likely through different
mechanisms, as shown by transcript and protein
analyses from the same silencing reactions. The d7
siRNA acts according to the typical RNAi mechanism,
in which mutant transcript level decrease is followed by
a decrease in mutant huntingtin. On the contrary, the
silencing of the mutant HTT allele by W13/16 seems to
occur predominantly, through translational repression,
what is suggested by the data presented in Figure 4. We
cannot exclude, however, some contribution from mRNA
cleavage mechanism (Supplementary Figure S5), and
deadenylation and degradation mechanism (not addressed
in this study), which was recently shown to be the major
mechanism by which miRNAs regulate their targets (20).
As previously demonstrated in miRNA and siRNA
studies, the increased number of target sites located in
the 30-UTR of exogenous transcripts facilitates gene
silencing (21,22). Here, we show that this phenomenon
occurs in overlapping target sites formed by CAG
repeats located in the ORF of endogenous HTT tran-
script. The observed preferential silencing of the
expanded HTT allele also indicates that the possession
of a higher number of target sites (rCAG units) is more
signiﬁcant than the effect of a more stable secondary
structure, which is likely to be formed by the expanded
CAG repeats in cells as it is in vitro (23,24).
The observation that W13/16 duplex does not discrim-
inate between the normal and mutant mRNAs of HTT
and ATXN3 genes with similar allele selectivity is
intriguing and the reason for this difference remains
unknown. The HTT and ATXN3 mRNAs differ in their
length, the localization of CAG repeat within ORF and in
the structural details of their CAG repeat regions. These
structural differences (23,25) are, however, unlikely to
account for differences in the silencing selectivity of
HTT and ATXN3 mRNAs as none of these structures
inhibits mutant transcript targeting by RISC.
Little is known about the antisense transcriptomes of
HTT and ATXN3 genes (26) which may be implicated in
generating differences in allele selectivity of their silencing.
This issue needs further exploration as silencing duplexes
composed of repeats may target both sense and antisense
transcripts spanning the repeat region and thus inﬂuence
their normal regulatory functions.
Finally, it was shown earlier that miRNA, fully comple-
mentary to target sequence, can induce mRNA cleavage,
and that siRNA forming mismatches with its target in the
ORF sequence can induce translational inhibition (27,28).
We demonstrated here that such mechanistic transition
also occurs for repeat-targeting reagents, which substan-
tially improves their gene and allele discriminating
properties.
The most intriguing discovery of this study was the ob-
servation that the transcriptional up-regulation of normal
huntingtin gene expression occurred together with trans-
lational mutant huntingtin inhibition. The transcriptional
activation of gene expression using duplex RNAs have
recently been demonstrated, and it has been shown that
RNAi comes in many types and that its activity is not
restricted to silencing effects (29–32). The upregulation
of normal HTT level could also result from some
unknown compensatory mechanism triggered by mutant
HTT silencing. The transcriptional activation and con-
comitant translational repression of the two alleles of
the same gene using repeat-targeting dsRNA is novel
from a mechanistic viewpoint and should be considered
a beneﬁcial feature from the perspective of HD therapy
using duplex RNA.
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